Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00065442

P6099clinical trial phasephase III clinical trialQ42824827
P582end time2009-01-01
P921main subjectcancer immunotherapyQ2012719
P1050medical conditionmetastatic prostate carcinomaQ55779807
prostate neoplasmQ56014511
P2899minimum age18
P1132number of participants512
P4844research interventionsipuleucel-TQ424057
P6153research siteNew York UniversityQ49210
University of CincinnatiQ153265
University of WashingtonQ219563
University of MinnesotaQ238101
University of Wisconsin–MadisonQ838330
Mayo ClinicQ1130172
Dana–Farber Cancer InstituteQ1159198
Indiana University – Purdue University IndianapolisQ1433199
Rush University Medical CenterQ1535116
Loyola University ChicagoQ1537759
Virginia Mason Medical CenterQ7934403
Nevada Cancer InstituteQ16932830
Cancer Care NorthwestQ30269598
Rocky Mountain Cancer CentersQ30270311
Urology Associates of North TexasQ30270635
Duke University Medical CenterQ30279912
Sharp HealthCare FoundationQ30288725
Northwell Health Orthopaedic InstituteQ33122159
University of Utah Health CareQ56582915
Icahn School of Medicine at Mount SinaiQ1950740
Baylor College of MedicineQ2892284
New York Medical CollegeQ4115972
Cleveland ClinicQ4117596
P859sponsorDendreonQ5256667
P580start time2003-07-01
P8363study typeinterventional studyQ78089383
P1476titleA Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma

Search more.